Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pulmonary Tuberculosis III01:31

Pulmonary Tuberculosis III

410
Tuberculosis (TB) is a contagious infection primarily affecting the lung parenchyma but which can also affect other body parts. TB can be classified based on disease development, presentation, and the affected anatomical site.
The first classification is based on the development of the disease, and it includes the following categories:
410
Disorders of Leukocytes01:27

Disorders of Leukocytes

1.0K
Leukocyte disorders can lead to either leukopenia, characterized by an abnormally low leukocyte count, or leukocytosis, marked by a very high leukocyte number.
Leukopenia may result from bone marrow disorders, autoimmune diseases, and infectious diseases. For example, conditions such as multiple myeloma and aplastic anemia can impair the bone marrow's ability to produce adequate leukocytes. Similarly, autoimmune diseases like lupus and viral infections such as HIV can prompt the immune...
1.0K
Pulmonary Tuberculosis IV01:26

Pulmonary Tuberculosis IV

186
Tuberculosis, more commonly referred to as TB, is an infectious disease stemming from Mycobacterium tuberculosis. While it primarily impacts the lungs, TB can also affect other body areas. Given its severity and global impact, timely and accurate diagnosis is crucial for controlling its spread and improving patient outcomes.
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
186
Pulmonary Tuberculosis II01:28

Pulmonary Tuberculosis II

296
Tuberculosis, or TB, is a bacterial infectious disease caused by Mycobacterium tuberculosis. While its primary impact is on the lungs, leading to pulmonary tuberculosis, it can also affect various other organs, a condition referred to as extrapulmonary tuberculosis.
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
296
Pulmonary Tuberculosis I01:29

Pulmonary Tuberculosis I

297
Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
297
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Selective Immune Tolerance: A Unifying Mechanism Linking Heavy Malaria Exposure, Waning Vaccine Antibodies, and Burkitt Lymphoma.

The Journal of infectious diseases·2026
Same author

Loss of systemic anti-viral immunity and LMP1-driven suppressive myeloid tumour niches converge to shape the immunobiology of Epstein-Barr virus-positive diffuse large B-cell lymphoma.

Leukemia·2026
Same author

Genomic heterogeneity in primary cutaneous follicular center lymphomas reveals different clinicopathological subgroups.

HemaSphere·2026
Same author

Applying Quality Oncology Practices in Africa: Lean Implementation, Real Impact.

American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting·2026
Same author

Modification of albendazole pharmacokinetics by menbutone administration in calves.

Frontiers in veterinary science·2026
Same author

The impact of pre-transplant extramedullary disease on the outcome of allogeneic hematopoietic cell transplantation for acute myeloid leukaemia in children- on behalf of PDWP/EBMT.

Bone marrow transplantation·2026

Related Experiment Video

Updated: Aug 17, 2025

Enhancing Tumor Content through Tumor Macrodissection
10:04

Enhancing Tumor Content through Tumor Macrodissection

Published on: February 12, 2022

10.4K

Burkitt lymphoma.

Cristina López1,2, Birgit Burkhardt3, John K C Chan4

  • 1Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.

Nature Reviews. Disease Primers
|December 15, 2022
PubMed
Summary
This summary is machine-generated.

Burkitt lymphoma (BL), an aggressive B cell cancer, involves MYC dysregulation and Epstein-Barr virus (EBV). While chemotherapy is effective, outcomes vary significantly based on geographic location and treatment access.

More Related Videos

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma
10:52

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma

Published on: March 30, 2018

11.2K
Establishment of Epstein-Barr Virus Growth-transformed Lymphoblastoid Cell Lines
06:38

Establishment of Epstein-Barr Virus Growth-transformed Lymphoblastoid Cell Lines

Published on: November 8, 2011

40.5K

Related Experiment Videos

Last Updated: Aug 17, 2025

Enhancing Tumor Content through Tumor Macrodissection
10:04

Enhancing Tumor Content through Tumor Macrodissection

Published on: February 12, 2022

10.4K
Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma
10:52

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma

Published on: March 30, 2018

11.2K
Establishment of Epstein-Barr Virus Growth-transformed Lymphoblastoid Cell Lines
06:38

Establishment of Epstein-Barr Virus Growth-transformed Lymphoblastoid Cell Lines

Published on: November 8, 2011

40.5K

Area of Science:

  • Hematology
  • Oncology
  • Genetics

Background:

  • Burkitt lymphoma (BL) is an aggressive B cell lymphoma impacting both children and adults.
  • BL is characterized by the t(8;14) chromosomal aberration, implicating MYC and Epstein-Barr virus (EBV) in its development.
  • Epidemiological variants include endemic, sporadic, and immunodeficiency-associated BL, with EBV status influencing classification.

Purpose of the Study:

  • To elucidate the molecular underpinnings and epidemiological variations of Burkitt lymphoma.
  • To highlight the diagnostic criteria and treatment strategies for BL.
  • To compare treatment outcomes in different global settings.

Main Methods:

  • Review of existing literature on Burkitt lymphoma.
  • Analysis of cytogenetic, molecular, and epidemiological data.
  • Comparison of treatment protocols and patient outcomes.

Main Results:

  • BL pathogenesis involves MYC dysregulation via immunoglobulin locus juxtaposition and potential EBV involvement.
  • Molecular alterations affect B cell receptor signaling, proliferation, survival, and chromatin remodeling.
  • Diagnosis relies on morphology and high MYC expression.
  • Chemotherapy is the primary treatment, with pediatric regimens adapted for adults.

Conclusions:

  • Subtyping BL into EBV-positive and EBV-negative may better reflect biological heterogeneity.
  • Treatment efficacy and outcomes are superior in high-income countries compared to low- and middle-income countries.
  • Timely diagnosis and access to effective chemotherapy are crucial for improving BL patient outcomes globally.